ArticleHaematologica2012
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.
Min Tang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it